These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25515636)

  • 1. New statistics on the cost of new drug development and the trouble with CNS drugs.
    Lindsley CW
    ACS Chem Neurosci; 2014 Dec; 5(12):1142. PubMed ID: 25515636
    [No Abstract]   [Full Text] [Related]  

  • 2. The extinction of drugs for clinical research: Can the ECNP medicines chest save them?
    Nutt D; Kilpatrick G; Hayes A
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534
    [No Abstract]   [Full Text] [Related]  

  • 3. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 4. CNS drug development. Part I: The early period of CNS drugs.
    Preskorn SH
    J Psychiatr Pract; 2010 Sep; 16(5):334-9. PubMed ID: 20859110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In this issue of Recent Patents on CNS Drug Discovery, focus is laid upon the potential development of new therapeutic drugs for neurological and affective disorders through targeting the endocannabinoid system. Introduction.
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):1-2. PubMed ID: 22384488
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
    Pangalos MN; Schechter LE; Hurko O
    Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2013 trends and statistics for prescription medications in the United States: CNS highest ranked and record number of prescriptions dispensed.
    Lindsley CW
    ACS Chem Neurosci; 2015 Mar; 6(3):356-7. PubMed ID: 25783498
    [No Abstract]   [Full Text] [Related]  

  • 8. Upcycling drugs for brain-related diseases: a sustainable future for targeted drug delivery.
    de Boer M; Visser CC; Gaillard PJ
    Ther Deliv; 2013 Apr; 4(4):435-8. PubMed ID: 23557284
    [No Abstract]   [Full Text] [Related]  

  • 9. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What regulatory science can bring for CNS drug development.
    Gispen-de Wied C; Stoyanova-Beninska V
    Eur Neuropsychopharmacol; 2015 Jul; 25(7):967-8. PubMed ID: 26024929
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges in developing drugs for neurological and psychiatric disorders.
    Simon NG; Brownstein MJ
    Prog Neurobiol; 2017 May; 152():1-2. PubMed ID: 28442128
    [No Abstract]   [Full Text] [Related]  

  • 12. Challenges and opportunities in neuroscience research.
    Coleman PJ; Barrow JC
    ChemMedChem; 2012 Mar; 7(3):339-41. PubMed ID: 22383223
    [No Abstract]   [Full Text] [Related]  

  • 13. Overview of the use of transgenic animals in CNS drug discovery.
    Nestler EJ; Olivier B
    Curr Protoc Pharmacol; 2001 May; Chapter 5():Unit5.20. PubMed ID: 21965073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An introduction to adaptive designs and adaptation in CNS trials.
    Dragalin V
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):153-8. PubMed ID: 20888739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mind how you go.
    Nature; 2013 Oct; 502(7470):141. PubMed ID: 24137753
    [No Abstract]   [Full Text] [Related]  

  • 16. The perfect storm: CNS drug development in trouble.
    Nierenberg AA
    CNS Spectr; 2010 May; 15(5):282-3. PubMed ID: 20448517
    [No Abstract]   [Full Text] [Related]  

  • 17. This first 2014 issue of Recent Patents in CNS Drug Discovery covers a range of rather diverse, but not necessarily unrelated topics. Introduction.
    Di Marzo V
    Recent Pat CNS Drug Discov; 2014 Apr; 9(1):1. PubMed ID: 24805823
    [No Abstract]   [Full Text] [Related]  

  • 18. CNS drug development: lessons learned part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approach.
    Preskorn SH
    J Psychiatr Pract; 2015 Jan; 21(1):60-6. PubMed ID: 25603452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and cost of new drugs acting on the central nervous system.
    Garattini S; Bertele' V
    Eur J Clin Pharmacol; 2003 May; 59(1):79-84. PubMed ID: 12743674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.